{
  "story_id": "8687af1eadd24ca988646ffb22f4a284",
  "desk": "drm3",
  "revision": 1,
  "published_at": "2026-11-20T09:36:10.000Z",
  "content_hash": "c6b3929cb3a4c4a5934a37b780186d643ff2cfeb909dd70e869b527f46f3c6ef",
  "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs",
  "basis": {
    "headline": "Daily pill daraxonrasib shows strong early pancreatic cancer trial results",
    "dek": "Experimental drug daraxonrasib halted tumor growth in 90% of pancreatic cancer trial patients.",
    "prose": "In early clinical trials, 90% of 61 late stage pancreatic cancer patients saw halted tumor growth when treated with daraxonrasib plus chemotherapy. [^1][^2][^3][^4]\n\nOver 60% of trial participants experienced shrinkage or full elimination of their pancreatic tumor during the study period. [^5] Researchers stated long term efficacy of daraxonrasib is not yet known, and additional extended trials will be conducted. [^6][^7]",
    "cited": "[{\"statement\":\"Approximately 8% (1 out of 12) trial patients had no detectable pancreatic tumor on CT scans after treatment with daraxonrasib.\",\"source\":\"Media Indonesia\",\"instrument\":\"News\",\"claim_key\":null,\"url\":\"https://mediaindonesia.com/kesehatan/958383/terobosan-kanker-pankreas-pil-harian-daraxonrasib-buat-tumor-hilang-di-pemindaian\"},{\"statement\":\"In early clinical trials, 90% of 61 late stage pancreatic cancer patients saw halted tumor growth when treated with daraxonrasib plus chemotherapy.\",\"source\":\"Media Indonesia\",\"instrument\":\"News\",\"claim_key\":null,\"url\":\"https://mediaindonesia.com/kesehatan/958383/terobosan-kanker-pankreas-pil-harian-daraxonrasib-buat-tumor-hilang-di-pemindaian\"},{\"statement\":\"In a trial of 61 advanced metastatic pancreatic cancer patients, 90% saw tumour growth stop while taking daraxonrasib.\",\"source\":\"The Guardian\",\"instrument\":\"News\",\"claim_key\":null,\"url\":\"https://www.theguardian.com/society/2026/nov/20/pill-pancreatic-cancer-breakthrough-daraxonrasib\"},{\"statement\":\"Daraxonrasib works by targeting and disabling KRAS gene mutations which drive most pancreatic cancer tumour growth.\",\"source\":\"The Guardian\",\"instrument\":\"News\",\"claim_key\":null,\"url\":\"https://www.theguardian.com/society/2026/nov/20/pill-pancreatic-cancer-breakthrough-daraxonrasib\"},{\"statement\":\"Over 60% of trial participants experienced shrinkage or full elimination of their pancreatic tumor during the study period.\",\"source\":\"Media Indonesia\",\"instrument\":\"News\",\"claim_key\":null,\"url\":\"https://mediaindonesia.com/kesehatan/958383/terobosan-kanker-pankreas-pil-harian-daraxonrasib-buat-tumor-hilang-di-pemindaian\"},{\"statement\":\"Researchers stated long term trials are still required, and daraxonrasib is not yet confirmed as a cure for pancreatic cancer.\",\"source\":\"Media Indonesia\",\"instrument\":\"News\",\"claim_key\":null,\"url\":\"https://mediaindonesia.com/kesehatan/958383/terobosan-kanker-pankreas-pil-harian-daraxonrasib-buat-tumor-hilang-di-pemindaian\"},{\"statement\":\"Researchers stated long term efficacy of daraxonrasib is not yet known, and additional extended trials will be conducted.\",\"source\":\"The Guardian\",\"instrument\":\"News\",\"claim_key\":null,\"url\":\"https://www.theguardian.com/society/2026/nov/20/pill-pancreatic-cancer-breakthrough-daraxonrasib\"}]",
    "kind": "news"
  },
  "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature",
  "receipt": {
    "slice_hash": "ae4ba3ed64fbb0125053be57696d560d8b8297bd51d88106bd2d1aaa3a943be8",
    "cursor_from": "ingest:raw_newsroomfloor.stories:ae4ba3ed64fbb012",
    "cursor_to": "ingest:raw_newsroomfloor.stories:ae4ba3ed64fbb012",
    "view": "ingest:raw_newsroomfloor.stories",
    "view_version": "1",
    "row_count": 1,
    "hash_basis": "sha256 over the JSON array of {insertId, json} rows as received (normalized wire shape), computed before the BigQuery forward",
    "credits": 0.01,
    "price_per_100_rows_written": 1,
    "sig": "xsvza49k-N70SVNLXo_L32HpzqLrX-EirRZL0bh8XhwiL_ya82cb7sXiJPKEudnZHx6fwfVzMPuDBtAYHhMcBw",
    "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
    "signer_path": "lakehouse/data-extract/v1",
    "alg": "Ed25519",
    "signed": true
  },
  "receipt_note": "the ingest door's signed receipt for this revision, verbatim as the door returned it",
  "generation_chain": {
    "wire": {
      "stream": "fountain_news",
      "story_id": "8dc33c897aa459e412b567903736d53c",
      "thread_id": "d2ac741f2df982ce6b05e6fb528683c6",
      "thread_label": "daraxonrasib",
      "novelty": "UPDATE",
      "content_hash": "12fbf5278593aacf99a8987d6d73e330b66ef057a90d0c17e5986117d262b24b",
      "compose": 3,
      "last_published_at": "2026-11-20T09:36:10.000Z",
      "read_receipt": {
        "slice_hash": "5b0f82e2a8ceb5b1de49fc11ad5cf5fd4af024d61e7fda8a785f9b7bcfbcfe77",
        "cursor_from": "eyJ0cyI6IjIwMjYtMTEtMjBUMDk6MjA6NTYuMDAwWiIsImlkIjoiYTRiM2ZhYTg2M2I1NGNiNjIxMzkwZjFiNzg5YmYxMDciLCJ2IjoiMSJ9",
        "cursor_to": "eyJ0cyI6IjIwMjYtMTEtMjBUMTI6MDQ6MDcuMDAwMDAwWiIsImlkIjoiN2RlMGFkNzY0ODgwMzFmOWU4ZjI4MjA3MDRmNzU2MWYiLCJ2IjoiMSJ9",
        "view": "v_fountain_news",
        "view_version": "1",
        "row_count": 71,
        "window_days": 3,
        "bytes_scanned": 2498337,
        "credits": 5.68,
        "price_per_100_rows": 8,
        "sig": "a9VqYm6LOx0dbFJ3OrTCEx7hslUBpFn7plotX_3mvplP_BotbIqhW80wbkA3S7ssT7djGiKhzUMbxu_QjgLdCw",
        "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
        "signer_path": "lakehouse/data-extract/v1",
        "alg": "Ed25519",
        "signed": true
      },
      "landing": "air"
    },
    "written_at": "2026-11-20T12:43:46.974Z"
  },
  "cited_facts": [
    {
      "n": 1,
      "statement": "Approximately 8% (1 out of 12) trial patients had no detectable pancreatic tumor on CT scans after treatment with daraxonrasib.",
      "source": "Media Indonesia",
      "instrument": "News",
      "claim_key": null,
      "url": "https://mediaindonesia.com/kesehatan/958383/terobosan-kanker-pankreas-pil-harian-daraxonrasib-buat-tumor-hilang-di-pemindaian",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 2,
      "statement": "In early clinical trials, 90% of 61 late stage pancreatic cancer patients saw halted tumor growth when treated with daraxonrasib plus chemotherapy.",
      "source": "Media Indonesia",
      "instrument": "News",
      "claim_key": null,
      "url": "https://mediaindonesia.com/kesehatan/958383/terobosan-kanker-pankreas-pil-harian-daraxonrasib-buat-tumor-hilang-di-pemindaian",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 3,
      "statement": "In a trial of 61 advanced metastatic pancreatic cancer patients, 90% saw tumour growth stop while taking daraxonrasib.",
      "source": "The Guardian",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.theguardian.com/society/2026/nov/20/pill-pancreatic-cancer-breakthrough-daraxonrasib",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 4,
      "statement": "Daraxonrasib works by targeting and disabling KRAS gene mutations which drive most pancreatic cancer tumour growth.",
      "source": "The Guardian",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.theguardian.com/society/2026/nov/20/pill-pancreatic-cancer-breakthrough-daraxonrasib",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 5,
      "statement": "Over 60% of trial participants experienced shrinkage or full elimination of their pancreatic tumor during the study period.",
      "source": "Media Indonesia",
      "instrument": "News",
      "claim_key": null,
      "url": "https://mediaindonesia.com/kesehatan/958383/terobosan-kanker-pankreas-pil-harian-daraxonrasib-buat-tumor-hilang-di-pemindaian",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 6,
      "statement": "Researchers stated long term trials are still required, and daraxonrasib is not yet confirmed as a cure for pancreatic cancer.",
      "source": "Media Indonesia",
      "instrument": "News",
      "claim_key": null,
      "url": "https://mediaindonesia.com/kesehatan/958383/terobosan-kanker-pankreas-pil-harian-daraxonrasib-buat-tumor-hilang-di-pemindaian",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 7,
      "statement": "Researchers stated long term efficacy of daraxonrasib is not yet known, and additional extended trials will be conducted.",
      "source": "The Guardian",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.theguardian.com/society/2026/nov/20/pill-pancreatic-cancer-breakthrough-daraxonrasib",
      "occurred_at": null,
      "published_at": null
    }
  ],
  "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true. The dates on cited_facts (occurred_at, published_at) are the forge's, joined at read time; they are not part of the signed basis above."
}